Literature DB >> 29214596

Preparing for the Future of Rare Diseases.

Stephen C Groft1, Manuel Posada de la Paz2.   

Abstract

Members of the rare disease community have devoted significant financial and personnel resources to address the numerous issues surrounding rare diseases. The past has been devoted to developing an emphasis on rare diseases including an emphasis on research studies or locating information on rare diseases and the requirements and limitations of conducting clinical trials with small patient populations. The expanded role of patient advocacy organizations and patient engagement in all aspects of clinical research continues to gain acceptance within the research community. The future will require a greater understanding and interpretation of available information from multiple sources including electronic health records and big data sources. The pipeline of potential orphan products continues to grow significantly and holds great promise for novel interventions due to advances in clinical trial design and data analyses. Expanding diagnostic procedures with improved sequencing methods will speed up the diagnosis or rare diseases. Accepting agreed upon nomenclature and codification of rare diseases will assist in differentiating diseases and identifying selected sub-populations of rare diseases. Improvements in patient recruitment and increased flexibility in the product review and approval procedures by regulatory agencies will facilitate product approvals. Children particularly will need help and assistance dealing with feelings of isolation from their peers due to their rare disease. During the transition from childhood to adolescence to adult, difficulties of fitting in with peers and not wanting to be different are a major concern. In response to increasing costs of treatments, Value-Based Care is gaining greater acceptance by the reimbursement and the payer community as a basis for payment for interventions. Mobile Health (M-health) Technologies have the potential to revolutionize how clinical research is conducted in the future. Wearable devices, remote sensors, and the development of mobile device applications (apps) will all assist in constant monitoring of patients for safety and efficacy of approved and investigational compounds. Tele Health and Tele Medicine may provide the necessary access to expert clinicians with a better understanding of individual rare diseases. The future promises great advances and even greater personalized treatments with the introduction of novel treatments and approaches to care.

Entities:  

Keywords:  Mobile health technologies; Orphan products; Patient-centric research; Rare diseases; Telehealth; Telemedicine; Transitional care; Value-based care

Mesh:

Year:  2017        PMID: 29214596     DOI: 10.1007/978-3-319-67144-4_34

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  What role can decentralized trial designs play to improve rare disease studies?

Authors:  J Moore; N Goodson; P Wicks; J Reites
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

2.  The Reliability of Telepractice Administration of the Western Aphasia Battery-Revised in Persons With Primary Progressive Aphasia.

Authors:  Leela A Rao; Angela C Roberts; Rhiana Schafer; Alfred Rademaker; Erin Blaze; Marissa Esparza; Elizabeth Salley; Christina Coventry; Sandra Weintraub; M-Marsel Mesulam; Emily Rogalski
Journal:  Am J Speech Lang Pathol       Date:  2022-02-17       Impact factor: 4.018

3.  Communication Bridge™-2 (CB2): an NIH Stage 2 randomized control trial of a speech-language intervention for communication impairments in individuals with mild to moderate primary progressive aphasia.

Authors:  Angela C Roberts; Alfred W Rademaker; Elizabeth Ann Salley; Aimee Mooney; Darby Morhardt; Melanie Fried-Oken; Sandra Weintraub; Marsel Mesulam; Emily Rogalski
Journal:  Trials       Date:  2022-06-13       Impact factor: 2.728

Review 4.  Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.

Authors:  Erik Tambuyzer; Benjamin Vandendriessche; Christopher P Austin; Philip J Brooks; Kristina Larsson; Katherine I Miller Needleman; James Valentine; Kay Davies; Stephen C Groft; Robert Preti; Tudor I Oprea; Marco Prunotto
Journal:  Nat Rev Drug Discov       Date:  2019-12-13       Impact factor: 84.694

Review 5.  Multifactorial Rare Diseases: Can Uncertainty Analysis Bring Added Value to the Search for Risk Factors and Etiopathogenesis?

Authors:  Domenica Taruscio; Alberto Mantovani
Journal:  Medicina (Kaunas)       Date:  2021-01-28       Impact factor: 2.430

6.  Investigator Experiences Using Mobile Technologies in Clinical Research: Qualitative Descriptive Study.

Authors:  Kevin Christopher McKenna; Cindy Geoghegan; Teresa Swezey; Brian Perry; William A Wood; Virginia Nido; Steve L Morin; Brigid K Grabert; Zachary P Hallinan; Amy L Corneli
Journal:  JMIR Mhealth Uhealth       Date:  2021-02-12       Impact factor: 4.773

Review 7.  How to design a national genomic project-a systematic review of active projects.

Authors:  Anja Kovanda; Ana Nyasha Zimani; Borut Peterlin
Journal:  Hum Genomics       Date:  2021-03-24       Impact factor: 4.639

8.  Stakeholders' views on drug development: the congenital disorders of glycosylation community perspective.

Authors:  Maria Monticelli; Rita Francisco; Sandra Brasil; Dorinda Marques-da-Silva; Tatiana Rijoff; Carlota Pascoal; Jaak Jaeken; Paula A Videira; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2022-07-30       Impact factor: 4.303

Review 9.  Rare lysosomal disease registries: lessons learned over three decades of real-world evidence.

Authors:  P K Mistry; P Kishnani; C Wanner; D Dong; J Bender; J L Batista; J Foster
Journal:  Orphanet J Rare Dis       Date:  2022-10-17       Impact factor: 4.303

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.